Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

The first OTC birth control is coming

An OTC birth control pill will help ensure more people can access the contraception they need without barriers

Salon

An overdose drug is finally over-the-counter. Is that enough to stop the death toll?

Narcan is now available in drug stores without a prescription. The nasal spray can save a life by stopping an opioid overdose. But will people pay the price and ask for it by name?

WEKU

The Surprise That Prompted Morphic Therapeutic To Dump 55% Over Two Days

Morphic stock plummeted Monday after the company's ulcerative colitis drug underperformed a rival. MORF stock has lost 55% over two days.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Prescription pilot just the tonic for pharmacists

Pharmacists will be able to prescribe medications and administer more vaccines under a pilot program being expanded throughout Queensland.

AAP

Draft patent amendment rules undermine pre-grant opposition

Draft patent rules threaten pre-grant opposition, a key public health safeguard. Big pharma seeks to remove essential safeguards from India’s patent laws, creating needless hurdles in pre-grant opposition. Draft rules introduce variable fees, power to determine maintainability of representation by individuals/groups. This threatens access to quality-assured, affordable generics & extends…

The Hindu

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

StockNews.com

Walgreens and CVS warned about selling illegal eye products

Warning letters sent to the companies claimed certain products they sell are ‘especially concerning from a public health perspective’

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Revolving door redux: The DEA's recently departed No. 2 returns to a Big Pharma consulting firm

Washington’s revolving door kept spinning this week as the Drug Enforcement Administration’s recently departed second-in-command returned for another stint with a high-powered consulting firm where he previously advised OxyContin maker Purdue Pharma

The Independent UK

Workplace drug testing quagmire deepens

Medical cannabis is behind an uptick in workplace drug detection and the solution isn't clear-cut, reports Andrew Bevin

Newsroom.co.nz

Xpert MTB/RIF molecular test for tuberculosis diagnosis to cost 20% less

Danaher Corporation, which sells the Xpert MTB/RIF molecular test for diagnosing tuberculosis (TB) and rifampicin resistance, has announced a lowering of the price of its standard TB test cartridge

The Hindu

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com

Three Scottish cities to apply for drug testing facilities, says minister

APPLICATIONS will be made for drug testing facilities in three Scottish cities, drugs policy minister Elena Whitham has said...

The National (Scotland)

Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke

Revance is reversing course to stay competitive with AbbVie's aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.

Investors Business Daily

Is Palatin Technologies (PTN) Stock a Biotech Buy Before Earnings?

Palatin Technologies’ (PTN) stock has plummeted more than 75% over the past year. Since its inception, the biotech company has incurred massive net losses and negative cash flows from operations. Further, it anticipates incurring additional losses in the future. So, let’s determine if PTN is a buy or sell before…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Expand pharmacy capabilities to ease pressure on GPs, think tanks say

The report outlined a number of recommendations for policymakers, as well as ‘significant’ barriers facing the sector.

StockNews.com

3 Healthcare Stocks to Buy Today

The POWR Ratings system points the way to 3 of the most attractive healthcare stocks on the market today. Read on below for why you should consider adding these 3 stocks to your portfolio: Johnson & Johnson (JNJ), Amgen (AMGN) and AbbVie (ABBV).

Investors Business Daily

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Investors Business Daily

These 7 Stocks Are Outperforming Nvidia In 2023

Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 996%, leading seven huge winners this year.

Get all your
news in one place.

100’s of premium titles.
One news app.

The National (Scotland)

Date set for Glasgow drug consumption room crunch talks

A KEY meeting to determine how the UK’s first safe drug consumption room could be trialled in Glasgow will go ahead before the end of this month,…

Investors Business Daily

How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug

Argenx is Friday's IBD Stock Of The Day. The biotech stock is climbing the right side of a cup base on enthusiasm for its drug, Vyvgart.

The Hindu

Businessline Millets Conclave: Krishna Ella calls for GST waiver for millets

StockNews.com

Which of these 3 Pharma Stocks Should You Buy, Hold or Sell?

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. So, let's analyze whether Johnson & Johnson (JNJ), Calliditas Therapeutics AB (CALT), and Aurora Cannabis (ACB) are a Buy, Hold, or Sell.

The Independent UK

Big Pharma's Johnson & Johnson under investigation in South Africa over 'excessive' drug prices

U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug

The Independent UK

Free prescription discount cards from GoodRx — What’s the catch?

GoodRx’s prescription savings program offers significant discounts on prescription drugs, but not without some catches

The Independent UK

Communities across Appalachia band together for first-ever 13-state Narcan distribution event

An effort to destigmatize the use of overdose reversal drugs that started as a pilot in two West Virginia counties has expanded to all thirteen states in Appalachia this year

1 … 29 30 31 32

People

King Charles III

12,851 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.